Severe mental illness and diabetes mellitus Type 2

Psychiatrie

Volumn 9, Issue 3, 2012, Pages 159-164

  De Hert, M ^a   Detraux, J ^a   Vancampfort, D ^a   Yu, W ^a   Correll, C U ^b,c,d,e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Diabetes mellitus; Severe mental illness

Indexed keywords

EID: 84867956207     PISSN: 16144864     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1671717     Document Type: Article

References (52)

1. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10(1): 52-77.
2. Whiting D, Unwin N, Roglic G. Diabetes: equity and social determinant. In: Blas E, Sivasankara Kurup A (eds). Equity, social determinant and public Health programmes. Geneva: World Health Organization, 2010: 77-94.
3. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008; 31(12): 2383-90.
4. Nasrallah HA, Meyer JM, Goff DC et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86: 15-22. (Pubitemid 44234064)
5. Frayne SM, Halanych JH, Miller DR et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med 2005; 165: 2631-38. (Pubitemid 41785061)
6. Desai MM, Rosenheck RA, Druss BG et al. Mental disorders and quality of diabetes care in the veterans health administration. Am J Psychiatry 2002; 159: 1584-90. (Pubitemid 35006741)
7. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012; 42(1): 125-147.
8. Holt RI, Abdelrahman T, Hirsch M et al. The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. J Psychopharmacol 2010; 24: 867-73.
9. Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, Willett WC, Ascherio A, Hu FB. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med 2010; 170(21): 1884-91.
10. Medved V, Jovanoviâ N, Knapiâ VP. The comorbidity of diabetes mellitus and psychiatric disorders. Psychiatr Danub 2009; 21(4): 585-8.
11. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24(6):1069-78. (Pubitemid 33716379)
12. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006; 23(11): 1165-73. (Pubitemid 44600576)
13. Wagner G, Icks A, Albers B, Abholz HH. [Type 2 diabetes mellitus and depressive symptoms: what is the cause of what? A systematic literature review]. Dtsch Med Wochenschr 2012; 137(11): 523-8.
14. Silva N, Atlantis E, Ismail K. A review of the association between depression and insulin resistance: pitfalls of secondary analyses or a promising new approach to prevention of type 2 diabetes? Curr Psychiatry Rep 2012; 14(1): 8-14. 15.
15. Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, Pouwer F; European Depression in Diabetes (EDID) Research Consortium. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia 2010; 53(12): 2480-6.
16. Nouwen A, Nefs G, Caramlau I, Connock M, Winkley K, Lloyd CE, Peyrot M, Pouwer F; European Depression in Diabetes Research Consortium. Prevalence of depression in individuals with impaired glucose metabolism or undiagnosed diabetes: a systematic review and meta-analysis of the European Depression in Diabetes (EDID) Research Consortium. Diabetes Care 2011; 34(3): 752-62.
17. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591-8.
18. Brown LC, Majumdar SR, Johnson JA. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract 2008; 79(1): 61-7.
19. Kivimäki M, Hamer M, Batty GD, Geddes JR, Tabak AG, Pentti J, Virtanen M, Vahtera J. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 2010; 33(12): 2611-6.
20. Kivimäki M, Tabák AG, Lawlor DA, Batty GD, Singh-Manoux A, Jokela M, Virtanen M, Salo P, Oksanen T, Pentti J, Witte DR, Vahtera J. Antidepressant use before and after the diagnosis of type 2 diabetes: a longitudinal modeling study. Diabetes Care 2010; 33(7): 1471-6.
21. Raeder MB, Bjelland I, Emil Vollset S, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry 2006; 67(12): 1974-82. (Pubitemid 46048196)
22. Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, Haffner SM, Price DW, Knowler WC; Diabetes Prevention Program Research Group. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008; 31(3): 420-6.
23. Rubin RR, Ma Y, Peyrot M, Marrero DG, Price DW, Barrett-Connor E, Knowler WC; Diabetes Prevention Program Research Group. Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care 2010; 33(12): 2549-51.
24. Khoza S, Barner JC, Bohman TM, Rascati K, Lawson K, Wilson JP. Use of antidepressants and the risk of type 2 diabetes mellitus: a nested case-control study. Int J Clin Pharm 2012; 34 (3): 432-438.
25. Kivimäki M, Batty GD, Jokela M, Ebmeier KP, Vahtera J, Virtanen M, Brunner EJ, Tabak AG, Witte DR, Kumari M, Singh-Manoux A, Hamer M. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? Biol Psychiatry 2011; 70(10): 978-84.
26. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001; 63(4): 619-30. (Pubitemid 32695143)
27. Atlantis E, Lange K, Goldney RD, Martin S, Haren MT, Taylor A, O'Loughlin PD, Marshall V, Tilley W, Wittert GA. Specific medical conditions associated with clinically significant depressive symptoms in men. Soc Psychiatry Psychiatr Epidemiol 2011; 46(12): 1303-12.
28. Barton DA, Dawood T, Lambert EA, Esler MD, Haikerwal D, Brenchley C, Socratous F, Kaye DM, Schlaich MP, Hickie I, Lambert GW. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens 2007; 25(10): 2117-24. (Pubitemid 47476310)
29. Bao AM, Meynen G, Swaab DF. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev 2008; 57(2): 531-553. (Pubitemid 351381758)
30. Dziemidok P, Makara-Studziska M, Jarosz MJ. Diabetes and depression: a combination of civilization and life-style diseases is more than simple problem adding - literature review. Ann Agric Environ Med 2011; 18 (2): 318-322.
31. Strine TW, Mokdad AH, Dube SR, Balluz LS, Gonzalez O, Berry JT, Manderscheid R, Kroenke K. The association of depression and anxiety with obesity and unhealthy behaviors among communitydwelling US adults. Gen Hosp Psychiatry 2008; 30(2):127-37. (Pubitemid 351248982)
32. de Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res 2010; 178(2): 230-5.
33. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67(3): 220-9.
34. Lysy Z, Da Costa D, Dasgupta K. The association of physical activity and depression in Type 2 diabetes. Diabet Med 2008; 25(10): 1133-41.
35. Mendelsohn C. Smoking and depression - a review. Aust Fam Physician 2012; 41(5): 304-7.
36. Casey DA, Rodriguez M, Northcott C, Vickar G, Shihabuddin L. Schizophrenia: medical illness, mortality, and aging. Int J Psychiatry Med 2011;41(3): 245-51.
37. Schoepf D, Potluri R, Uppal H, Natalwala A, Narendran P, Heun R. Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year followup. Eur Psychiatry 2012; 27(1): 33-42.
38. Becker T, Hux J. Risk of acute complications of diabetes among people with schizophrenia in Ontario, Canada. Diabetes Care 2011; 34(2): 398-402.
39. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008; 192(6): 406-11. (Pubitemid 351809892)
40. Liao CH, Chang CS, Wei WC, Chang SN, Liao CC, Lane HY, Sung FC. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res 2011; 126(1-3): 110-6.
41. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012; 8(2): 114-126.
42. Guo JJ, Keck PE Jr, Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested casecontrol study. Pharmacotherapy 2007; 27: 27-35. (Pubitemid 46067960)
43. Guo JJ, Keck PE Jr, Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population- based, case-control study. J Clin Psychiatry 2006; 67: 1055-61. (Pubitemid 44230876)
44. Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010; 197(4): 266-71.
45. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010; 35(9):1997-2004.
46. De Hert M, Yu WP, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone, and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012, in press.
47. Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: an age-related association. Ann Pharmacother 2008; 42(9): 1316-22.
48. De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, Newcomer JW, Uwakwe R, Asai I, Möller HJ, Gautam S, Detraux J, Correll CU. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011; 10(2): 138-51.
49. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011; 17(2): 97-107.
50. Buchholz S, Morrow AF, Coleman PL. Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Intern Med J 2008; 38(7): 602-6.
51. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - a systematic review and metaanalysis. Schizophr Bull 2011 Dec 29.
52. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010; 25 Suppl 2: S12-21.